Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

KC Pharmaceuticals

Tracked across 32 events · 384 articles · First seen May 07, 2025 · Last active Sep 03, 2026

Sentiment
15
Attention
7
Events
32
Relationships
4
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 0
Regulatory
Impact: The KC Pharmaceuticals issued new advice warning against prolonged use of nasal decongestant sprays.
Jan 08, 2026 · 6 articles
2 10
Business
Impact: KC Pharmaceuticals will participate in two investor conferences in June 2026, providing an opportunity to engage with investors and potentially increase visibility and investor interest in the company.
May 27, 2026 · 6 articles
2 -30
Regulatory
Impact: Initiator of the recall; faces potential reputational damage and financial liability.
Jul 24, 2026 · 12 articles
4 60
Business
Impact: Supernus is a merging party, contributing its CNS portfolio and CEO. Its shareholders receive Indivior shares, and the combined entity retains its name and ticker, with shares rising on the announcement.
Aug 03, 2026 · 6 articles
2 -10
Domestic
Impact: KC Pharmaceuticals accepted the resignation of its finance head, Rajkumar Bafna, due to India — Delhi's air pollution, highlighting potential challenges in retaining talent in affected regions.
Dec 28, 2025 · 11 articles
4 70
Tech
Impact: KC Pharmaceuticals, a subsidiary of Suzhou Ribo Life Science Company, is a key collaborator in the siRNA partnership with KC Pharmaceuticals, Inc., successfully reaching a drug nomination milestone for MASH therapies.
Jul 02, 2026 · 7 articles
3 50
Business
Impact: Azurity gains exclusive commercialization rights to D-PLEX100 in the U.S. and Canada, expanding its specialty pharmaceutical portfolio. It will fund clinical development for label expansion, positioning for future revenue.
Jul 21, 2026 · 7 articles
4 80
Tech
Impact: As Ribo's subsidiary focused on global development, Ribocure is instrumental in executing the clinical trials and will lead further development of vortosiran.
Jul 22, 2026 · 8 articles
2 -15
Regulatory
Impact: As the parent company of Unique Pharmaceutical Laboratories, KC Pharmaceuticals faces potential reputational damage and scrutiny over manufacturing quality control.
Jul 21, 2026 · 7 articles
2 10
Business
Impact: Centessa achieved the late-stage development milestone in its OX2R agonist portfolio, triggering the payment to Nxera. As a wholly-owned subsidiary of Eli Lilly, its progress contributes to Lilly's pipeline.
Sep 03, 2026 · 6 articles
4 60
Business
Impact: KC Pharmaceuticals>>> is a key company in the pre-filled syringe market, contributing to its expansion.
May 25, 2026 · 6 articles
2 55
Business
Impact: Centessa was acquired by Eli Lilly, completing a transaction that validates the value of its orexin receptor agonist programs. Nxera retains rights to future payments from these programs.
Aug 07, 2026 · 6 articles
2 -10
Domestic
Impact: Victim of counterfeiting; filed the complaint that triggered the investigation, protecting its brand integrity.
Aug 27, 2026 · 6 articles
2 10
Business
Impact: KC Pharmaceuticals is one of the publicly traded companies presenting at the conference, seeking to attract investors and showcase its innovations.
Apr 02, 2026 · 7 articles
6 85
Tech
Impact: Licensee of the vaccine technology; positive trial results could increase its valuation and attract investment.
Jul 16, 2026 · 21 articles
7 55
International
Impact: KC Pharmaceuticals is vertically integrating the entire supply chain for authentic herbs, accelerating the global expansion of Chinese TCM and heritage wellness brands.
Jun 15, 2026 · 87 articles
6 -40
International
Impact: Added to the UFLPA Entity List, restricting its pharmaceutical exports to the U.S.
Jul 31, 2026 · 20 articles
2 50
Regulatory
Impact: The KC Pharmaceuticals is involved in the establishment of joint oversight committees with the Nigeria — National Drug Law Enforcement Agency to strengthen monitoring of regulated medicines and improve intelligence sharing.
Jun 26, 2026 · 7 articles
4 10
Business
Impact: KC Pharmaceuticals became a new shareholder in Adani Group as part of the acquisition settlement.
Jul 02, 2026 · 6 articles
0 0
Business
Impact: KC Pharmaceuticals is mentioned as a previous employer of Suman Subramanian, providing context to his experience.
Aug 10, 2026 · 6 articles
1 5
Business
Impact: KC Pharmaceuticals, 64% owned by Lobe, is mentioned as a subsidiary developing L-130 for neurological disorders. The private placement is not directly allocated to Cynaptec, but the company benefits from Lobe's overall financial health.
Aug 12, 2026 · 7 articles
2 -10
Regulatory
Impact: Mentioned as a prior recaller; context for industry-wide sterility issues.
Aug 20, 2026 · 6 articles
4 -10
Accidents
Impact: KC Pharmaceuticals is mentioned as a recent cyberattack victim, underscoring the sector's vulnerability but not directly affected by this event.
Aug 26, 2026 · 16 articles
2 0
Business
Impact: KC Pharmaceuticals is a majority-owned subsidiary of Lobe Sciences and is mentioned as part of Lobe's strategic development, though not directly impacted by this specific private placement.
Apr 11, 2026 · 7 articles
3 0
Business
Impact: Adamas Pharmaceuticals>>> was sold to KC Pharmaceuticals>>>.
May 19, 2026 · 6 articles
4 -10
Accidents
Impact: Mentioned as one of the healthcare companies recently affected by cyberattacks, highlighting sector-wide vulnerability.
Jul 31, 2026 · 6 articles
4 0
Business
Impact: KC Pharmaceuticals was acquired by AstraZeneca, serving as a comparable deal in the radiopharmaceutical sector.
Aug 03, 2026 · 7 articles
2 10
Business
Impact: Portfolio company of Tata Capital Healthcare Fund II; mentioned as part of the fund's track record.
Aug 17, 2026 · 6 articles
3 0
Regulatory
Impact: KC Pharmaceuticals was involved in a prior unrelated eye drop recall; mentioned for context but not directly affected.
Jul 07, 2026 · 38 articles
4 0
Business
Impact: KC Pharmaceuticals was acquired by AbbVie in 2024 for an experimental psychedelic depression therapy, illustrating the competitive landscape.
Jul 16, 2026 · 25 articles
+ 2 more events View on Dashboard
ERGEN INTELLIGENCE
Track KC Pharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.